---
title: "CHINARES PHARMA's DC6001 tablets and metronidazole gel approved for clinical use and market launch"
description: "CHINARES PHARMA announced that its subsidiary Beijing Shuanghe Runchuang Technology's DC6001 tablets have received clinical trial approval from the National Medical Products Administration for the tre"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/270693578.md"
published_at: "2025-12-24T06:12:19.000Z"
---

# CHINARES PHARMA's DC6001 tablets and metronidazole gel approved for clinical use and market launch

> CHINARES PHARMA announced that its subsidiary Beijing Shuanghe Runchuang Technology's DC6001 tablets have received clinical trial approval from the National Medical Products Administration for the treatment of hereditary macular degeneration in adolescents. At the same time, the metronidazole gel of China Resources Sanjiu Pharmaceutical Co., Ltd. has been approved for market launch, suitable for local treatment of various skin inflammations

CHINARES PHARMA (03320.HK) announced that its subsidiary Beijing Shuanghe Runchuang Technology has received the "Drug Clinical Trial Approval Notice" for DC6001 tablets issued by the National Medical Products Administration. At the same time, the metronidazole gel of the group's subsidiary China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. has been approved for marketing by the National Medical Products Administration.

DC6001 tablets are intended for the treatment of Stargardt disease, a hereditary macular degeneration in adolescents.

Metronidazole is a broad-spectrum antibacterial drug that can effectively kill and inhibit anaerobic bacteria, with significant anti-inflammatory and immunomodulatory effects. It is suitable for the local treatment of inflammatory papules, pustular lesions, and rosacea erythema. It is also recommended as a first-line medication in domestic and international guidelines for rosacea. The gel formulation has good permeability, a refreshing skin feel, and is convenient to use, better meeting patients' needs for local treatment medications for the skin

### Related Stocks

- [03320.HK - CHINARES PHARMA](https://longbridge.com/en/quote/03320.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 閲文集團是否會翻開新篇章？ | 閲文集團預計去年淨虧損高達 8.5 億元，主要由於收購新經典傳媒時計提了 18 億元的商譽減值。該公司的股票經歷了顯著的波動，在達到每股 45.50 港元的高點後下跌了 20%，並在發佈盈利預警後最近又下跌了 8%。儘管面臨收入和核心業務下 | [Link](https://longbridge.com/en/news/276113491.md) |
| NVIDIA 的新芯片將使成本降低 35 倍，同時編碼工具佔據了 AI 相關搜索的一半 | NVIDIA 推出了其 GB300 NVL72 系統，該系統通過每兆瓦處理 50 倍於舊 Hopper 平台的工作量，顯著提高了效率，從而使每處理的信息成本降低了 35 倍。人工智能工具市場正在快速擴張，AI 編碼助手現在幾乎佔據了與 AI | [Link](https://longbridge.com/en/news/276081422.md) |
| Yotta 數據服務宣佈將部署 20,736 個液冷 NVIDIA Blackwell Ultra GPU | Yotta Data Services 計劃部署 20,736 個液冷 NVIDIA Blackwell Ultra GPU，投資超過 20 億美元，打造亞洲最大的 AI 超級集羣之一。該項目預計將在 2026 年 8 月上線，提升印度在  | [Link](https://longbridge.com/en/news/276218630.md) |
| 08:00 食物過敏診斷因機器學習和深度學習 AI 模型的應用而得到提升 | 機器學習和深度學習人工智能模型顯著提升了食物過敏的診斷，準確率比傳統方法（如皮膚點刺測試和特異性 IgE 測量）提高了 40%。先進的深度學習模型進一步提高了 10-15% 的性能。這項研究在 2026 年 AAAAI 年會上發佈，表明這些 | [Link](https://longbridge.com/en/news/275980083.md) |
| 表格 - 亞洲實物橡膠價格 - 2 月 17 日 | 2 月 17 日（路透社）- 價格 泰國 RSS3（3 月）74.07 泰銖/公斤 泰國 STR20（3 月）65.88 泰銖/公斤 泰國 60% 乳膠（散裝/3 月）50.46 泰銖/公斤 馬來西亞 SMR20（3 月）不適用 印度尼西亞 | [Link](https://longbridge.com/en/news/276104536.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.